DelSiTech and Anticancer Bioscience Announce a Collaboration Agreement for the Development of Long-acting Therapies in Oncology Ossi Leppänen2022-05-18T11:21:41+02:00May 18th, 2022| Read More
DelSiTech is recruiting highly motivated drug development professionals for exciting key positions at the company facility in Turku, Finland. Ossi Leppänen2022-05-13T14:04:23+02:00May 13th, 2022| Read More
BIO International Convention San Diego June, 13-16 Ossi Leppänen2022-05-06T16:13:17+02:00May 6th, 2022| Read More
6th international Conference on Drug Delivery and Formulations 2022 Edinburgh, May 18-19 Ossi Leppänen2022-04-06T18:36:43+02:00April 6th, 2022| Read More
DelSiTech to Present at ARVO 2022 Denver, May 1-4 Ossi Leppänen2022-04-06T18:05:31+02:00April 6th, 2022| Read More
CRS LNP-RNA Therapeutics Symposium 2022, April 6-7 Ossi Leppänen2022-04-06T16:42:59+02:00April 6th, 2022| Read More
DelSiTech Enters into an Exclusive Licensing Agreement with Optifye Therapeutics for the Development of a Controlled Release Ophthalmic Eye Drop Product Ossi Leppänen2022-03-28T11:32:06+02:00March 28th, 2022| Read More
DelSiTech Ltd Announces Appointment of Mr. Kristian Rantala as Chief Financial Officer Ossi Leppänen2022-02-03T14:13:45+02:00February 3rd, 2022| Read More
BIO Europe Spring 2021, March 28-31 Ossi Leppänen2022-01-31T18:13:11+02:00January 31st, 2022| Read More
DelSiTech Ltd Announces the Appointment of Dr. Outi Heikkilä, as the New Director, Head of Manufacturing. Ossi Leppänen2022-01-28T12:13:31+02:00January 27th, 2022| Read More
